Why the study?
Does the newly developed radioimmunoassay perform better than a commercially available kit for measuring GnRH in plasma and urine?
Does the newly developed radioimmunoassay perform better than a commercially available kit for measuring GnRH in plasma and urine?
The newly developed radioimmunoassay is suitable for measuring high concentrations of GnRH in patients receiving pulsatile infusions, overcoming the limitations of a commercially available kit.
May support GnRH measurement during pulsatile therapy in research; leaves open clinical adoption pending validation.
A radioimmunoassay for the measurement of gonadotrophin releasing hormone (GnRH) in plasma and urine using readily available reagents was developed. The GnRH assay showed good precision, recovery, and parallelism over a wide range of GnRH concentrations with a sensitivity of 15 pg/ml. The assay was compared with a commercially available kit (Buhlmann Laboratories). Although the Buhlmann kit showed acceptable precision, recovery, sensitivity, and correlation with the developed GnRH assay for plasma samples, lack of parallelism of serially diluted plasma and urine samples was consistently observed, together with a poor correlation with the developed GnRH assay for urine, suggesting a matrix effect with the Buhlmann kit. The developed assay is suitable for measuring GnRH in samples obtained from patients receiving pulsatile infusions of GnRH. In contrast, the commercially available Buhlmann kit was unsuitable for measuring plasma GnRH as the kit had a top standard of only 160 pg/ml, well below the peak plasma concentration. It would not be possible to dilute samples for analysis because of the lack of parallelism of diluted samples compared with standards obtained with the Buhlmann assay.
No takes yet. Share an insight, caveat, or question.
A 1998 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: